Locus Biosciences Inc.

Locus Biosciences is developing CRISPR-engineered bacteriophage (“crPhage”) products that kill target bacteria by irreversibly destroying their DNA while leaving the many species of beneficial bacteria in the body unharmed.

Total Equity Investment: $35M+